{
    "clinical_study": {
        "@rank": "3226", 
        "arm_group": {
            "arm_group_label": "BGJ398X", 
            "arm_group_type": "Experimental", 
            "description": "To estimate anti-tumor efficacy of BGJ398"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to\n      patients with recurrent GBM, whose tumors demonstrate FGFR amplification, translocation, or\n      activating mutation."
        }, 
        "brief_title": "A Phase 2 Study of BGJ398 in Patients With Recurrent GBM", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "detailed_description": {
            "textblock": "Patients will be enrolled in two groups. Group 1 will enroll patients who are not candidates\n      for surgery. Group 2 will enroll patients who are surgical candidates. Patients from both\n      groups will be evaluated for tumor response and progression by MRI every 8 weeks until\n      disease progression or discontinuation from study using RANO criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Patients with histologically confirmed GBM at the time of diagnosis or prior relapse.\n\n          2. Documentation of amplification, translocation, or activating mutation to FGFR1,\n             FGFR2, or FGFR3, or FGFR4\n\n          3. RANO defined tumor progression by MRI  in comparison to a prior scan\n\n          4. Patients must have received prior external beam radiotherapy and temozolomide.\n\n        Exclusion criteria:\n\n          1. History of another primary malignancy\n\n          2. Prior or current treatment with a FGFR inhibitor\n\n          3. Neurological symptoms related to underlying disease requiring increasing doses of\n             corticosteroids\n\n          4. Patients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED).  If\n             previously on an EIAED, the patient must be off of it for at least two weeks prior to\n             study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975701", 
            "org_study_id": "CBGJ398X2201"
        }, 
        "intervention": {
            "arm_group_label": "BGJ398X", 
            "description": "Capsule for oral use.", 
            "intervention_name": "BGJ398", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "BGJ398,", 
            "recurrent glioblastoma'", 
            "recurrent GBM,", 
            "FGFR,"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "annettetan@mednet.ucla.edu", 
                    "last_name": "Annette Tan", 
                    "phone": "310-794-3521"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles Dept. of Neuro-Oncology"
                }, 
                "investigator": {
                    "last_name": "Timothy F. Cloughesy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "munozt@neurosurg.ucsf.edu", 
                    "last_name": "Thelma Munoz", 
                    "phone": "415-353-2523"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94101"
                    }, 
                    "name": "University of California San Francisco Dept of Onc."
                }, 
                "investigator": {
                    "last_name": "Nicolas Butowski", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University Dept of Onc"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "katie-mccarthy@northwestern.edu", 
                    "last_name": "Katie McCarthy", 
                    "phone": "312-695-1371"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Jeffrey J. Raizer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "meaghan_elliott@dfci.harvard.edu", 
                    "last_name": "Meaghan Elliott", 
                    "phone": "617-632-2166"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute SC"
                }, 
                "investigator": {
                    "last_name": "Patrick Y. Wen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "km2965@columbia.edu", 
                    "last_name": "Katlyn McBergin", 
                    "phone": "212-305-9858"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center- New York Presbyterian Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Andrew B. Lassman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Denise.rodriguez@nyumc.org", 
                    "last_name": "Denise Rodriguez", 
                    "phone": "646-801-1017"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Langone Medical Center Oncology Dept"
                }, 
                "investigator": {
                    "last_name": "Howard Fine", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center Duke - Baker"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "sona.hardikar@osumc.edu", 
                    "last_name": "Sona Hardikar", 
                    "phone": "614-688-7592"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept of Onc."
                }, 
                "investigator": {
                    "last_name": "Vinay Puduvalli", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute SC - 2"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "MKHANMD@ACRCTRIALS.COM", 
                    "last_name": "Muhammad Khan", 
                    "phone": "512-421-4100"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75251"
                    }, 
                    "name": "Texas Oncology, P.A. SC"
                }, 
                "investigator": {
                    "last_name": "Morris Groves", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "US Oncology Central Monitoring"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "wcwu@mdanderson.org", 
                    "last_name": "Winnie Wu", 
                    "phone": "713-745-5769"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas/MD Anderson Cancer Center SC-3"
                }, 
                "investigator": {
                    "last_name": "John F DeGroot", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Herblain cedex", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53105"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO", 
                        "zip": "40139"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "state": "the Netherlands", 
                        "zip": "3508 GA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 GD"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hospitalet de LLobregat", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08907"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "SE-171 76"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Z\u00fcrich", 
                        "country": "Switzerland", 
                        "zip": "8091"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Belgium", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Spain", 
                "Sweden", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: National Agency for the Safety of Medicine and Health Products", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Netherlands: Medicines Evaluation Board", 
                "Italy: Italian Medicines Agency", 
                "Spain: Spanish Agency for Medicines and Health Products", 
                "Switzerland: Swiss Agency for Therapeutic Products", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the anti-tumor activity of BGJ398 for patients with GBM with an amplification, translocation, or activating mutation in FGFR1,2,3 or 4, based on PFS6 (PFS rate at 6 months as defined by RANO criteria as assessed by the investigator)", 
            "measure": "progression free survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975701"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To further assess the anti-tumor activity of BGJ398 for patients with GBM with an amplification, translocation, or activating mutation in FGFR1,2,3 or 4, based on Overall Response Rate (ORR - patients with measurable disease - as defined by RANO criteria as assessed by the investigator", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "8 months after last patient last visit"
            }, 
            {
                "description": "To further assess the anti-tumor activity of BGJ398 for patients with GBM with an amplification, translocation, or activating mutation in FGFR1,2,3 or 4, based on Overall Survival", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "8 months after LPLV"
            }, 
            {
                "description": "Safety: type, frequency, and severity of AEs and SAEs; Tolerability: dose interruptions, reductions and dose intensity, and evaluations of laboratory values", 
                "measure": "safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "8 months after LPLV"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}